These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20409582)

  • 21. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
    Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
    Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M; Elmaagacli AH
    Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
    Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
    Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
    Holtz MS; Forman SJ; Bhatia R
    Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients.
    Wei Y; Stockelberg D; Hullberg S; Ricksten A; Wadenvik H
    Acta Haematol; 2007; 117(2):83-90. PubMed ID: 17106192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
    Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
    Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
    Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses.
    Speletas M; Argentou N; Karanikas V; Gramoustianou ES; Mandala E; Braimi M; Matsouka P; Ritis K; Germenis AE
    Clin Immunol; 2011 May; 139(2):155-63. PubMed ID: 21342791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.
    Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K
    Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
    Oehler VG; Guthrie KA; Cummings CL; Sabo K; Wood BL; Gooley T; Yang T; Epping MT; Shou Y; Pogosova-Agadjanyan E; Ladne P; Stirewalt DL; Abkowitz JL; Radich JP
    Blood; 2009 Oct; 114(15):3299-308. PubMed ID: 19625708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.